Therapeutic Strategies for Managing BPH Progression

European Urology, Supplements

Volumn 5, Issue 20, 2006, Pages 997-1003

  Fitzpatrick, John M ^a   Artibani, Walter ^b  

^a MATER PRIVATE HOSPITAL   (Ireland)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

5 Reductase inhibitors; BPH; Disease progression; LUTS; TURP

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; PLACEBO; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

ARTICLE; DAILY LIFE ACTIVITY; DISEASE COURSE; DRUG SAFETY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HUMAN; KIDNEY FAILURE; LIBIDO DISORDER; MORBIDITY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RISK REDUCTION; URINARY TRACT INFECTION; URINE INCONTINENCE; URINE RETENTION;

EID: 33750494739     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2006.08.009     Document Type: Article

References (44)

1. Jepsen J.V., and Bruskewitz R.C. Clinical manifestation and indications for treatment. In: Lepor H. (Ed). Prostatic diseases (2000), WB Saunders, Philadelphia 123-142
2. Reynard J.M., Peters T.J., Lamond E., and Abrams P. The significance of abdominal straining in men with lower urinary tract symptoms. Br J Urol 75 (1995) 148-153
3. Jaffe W.I., and Te A.E. Overactive bladder in the male patient: epidemiology, etiology, evaluation, and treatment. Curr Urol Rep 6 (2005) 410-418
4. Gades N.M., Jacobson D.J., Girman C.J., Roberts R.O., Lieber M.M., and Jacobsen S.J. Prevalence of conditions potentially associated with lower urinary tract symptoms in men. BJU Int 95 (2005) 549-553
5. Berry S.J., Coffey D.S., Walsh P.C., and Ewing L.L. The development of human benign prostatic hyperplasia with age. J Urol 132 (1984) 474-479
6. Girman C.J., Jacobsen S.J., Guess H.A., et al. Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol 153 (1995) 1510-1515
7. Jacobsen S.J., Girman C.J., Guess H.A., Rhodes T., Oesterling J.E., and Lieber M.M. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 155 (1996) 595-600
8. Roberts R.O., Jacobsen S.J., Jacobsen D.J., Rhodes T., Girman C.J., and Lieber M.M. Longitudinal changes in peak urinary flow rates in a community-based cohort. J Urol 163 (2000) 107-113
9. Rhodes T., Girman C.J., Jacobsen D.J., Roberts R.O., Lieber M.M., and Jacobsen S.J. Longitudinal prostate volume in a community-based sample: 7 year follow up in the Olmsted County Study of urinary symptoms and health status among men. J Urol 163 (2000) 249 (abstract no. 1105)
10. Roberts R.O., Lieber M.M., Jacobson D.J., Girman C.J., and Jacobsen S.J. Limitations of using outcomes in the placebo arm of a clinical trial of benign prostatic hyperplasia to quantify those in the community. Mayo Clin Proc 80 (2005) 759-764
11. Emberton M. The hallmarks of BPH progression and risk factors. Eur Urol Suppl 2 8 (2003) 2-7
12. Jacobsen S.J., Jacobson D.J., Girman C.J., et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 158 (1997) 481-487
13. Roehrborn C.G., McConnell J.D., Lieber M., et al. Serum prostate-specific antigen concentrations a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 53 (1999) 473-480
14. Crawford E.D., Wilson S.S., McConnell J.D., et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 175 (2006) 1422-1427
15. Teillac P. Relief of BPO or improvement in quality of life?. Eur Urol 34 (1998) 3-9
16. Kawakami J., and Nickel J.C. Acute urinary retention and surgery for benign prostatic hyperplasia: the patient's perspective. Can J Urol 6 (1999) 819-822
17. Andersen J.T., Nickel J.C., Marshall V.R., Schulman C.C., and Boyle P. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 49 (1997) 839-845
18. Teillac P. Benign prostatic hyperplasia: patients' perception of medical treatment and their expectations: results of a French survey involving patients treated with finasteride. Therapie 57 (2002) 473-483
19. de la Rosette J.J.M.C.H., Alivizatos G., Madersbacher S., et al. EAU guidelines on benign prostatic hyperplasia (BPH). Eur Urol 40 (2001) 256-263
20. Sech S.M., Montoya J.D., Bernier P.A., et al. The so-called "placebo effect" in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring. Urology 51 (1998) 242-250
21. Moyad M.A. The placebo effect and randomized trials: analysis of conventional medicine. Urol Clin North Am 29 (2002) 125-133
22. Lepor H. Pathophysiology, epidemiology, and natural history of BPH. Rev Urol 6 Suppl 9 (2004)
23. Djavan B., and Marberger M. A meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36 (1999) 1-13
24. Lepor H., Williford W.U., Barry M.J., et al. The impact of medical therapy on bother due to symptoms, quality of life and global outcome and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. J Urol 160 (1998) 1358-1367
25. McConnell J.D., Roehrborn C.G., Bautista O., et al. The long-term effects of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387-2398
26. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1. Diagnosis and treatment recommendations. J Urol 170 (2003) 530-547
27. AUA Guidelines on BPH 2003. http://www.auanet.org/guidelines/bph.cfm.
28. Roehrborn C.G., and McNicholas T. The management of prostatic obstruction: how to determine the best options?. Eur Urol Suppl 2 8 (2003) 13-19
29. Hartung R. Do alpha-blockers prevent the occurrence of acute urinary retention?. Eur Urol 39 (2001) 13-18
30. Desgrandchamps F., De La Taille A., Doublet J.D., and RetenFrance Study Group. The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia. BJU Int 97 (2006) 727-733
31. Clark R.V., Hermann D.J., Cunningham G.R., Wilson T.H., Morrill B.B., and Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor. J Clin Endocrinol Metab 89 (2004) 2179-2184
32. O'Leary M.P., Roehrborn C., Andriole G., Nickel C., Boyle P., and Hofner K. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5α-reductase inhibitor. BJU Int 92 (2003) 262-266
33. Debruyne F., Barkin J., van Erps P., et al. Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 46 (2004) 488-494
34. Madersbacher S., Alivizatos G., Nordling J., Sanz C.R., Emberton M., and de la Rosette J.J. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46 (2004) 547-554
35. Gormley G.J., Stoner E., Bruskewitz R.C., et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 327 (1992) 1185-1191
36. McConnell J.D., Bruskewitz R., Walsh P., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 338 (1998) 557-563
37. Boyle P., Roehrborn C., Harkaway R., Logie J., de la Rosette J., and Emberton M. 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. Eur Urol 45 (2004) 620-627
38. de la Rosette J.J., Kortmann B.B., Rossi C., et al. Long-term risk of retreatment of patients using α-blockers for lower urinary tract symptoms. J Urol 167 (2002) 1734-1739
39. Jaffe J.S., Ginsberg P.C., and Harkaway R.C. Prostate size and PSA predict failure in patients undergoing α blocker monotherapy. J Urol 165 (2001) 262 (abstract no. 1078)
40. Boyle P., Gould A.L., and Roehrborn C.G. Prostate volume predicts the outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials. Urology 48 (1996) 398-405
41. Boyle P., Roehrborn C.G., Marks L., Vela-Navarette R., and Nickel J.C. The novel dual 5α-reductase inhibitor dutasteride is effective for the treatment and prevention of complications in men with a PV 30 ≤ 40 cc and 40 cc. Eur Urol Suppl 2 1 (2003) 160 (abstract no. 632)
42. Dutasteride SPC. Accessed at http://emc.medicines.org.uk.
43. McConnell J.D., Roehrborn C.G., Bautista O., et al. The long-term effects of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387-2398
44. Barkin J., Guimaraes M., Jacobi G., Pushkar D., Taylor S., van Vierssen Trip O.B., and on behalf of the SMART-1 Investigator Group. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride. Eur Urol 44 (2003) 461-466